Ligand Pharmaceuticals Incorporated (FRA:LGDN)
Germany · Delayed Price · Currency is EUR 160.00
+4.00 (2.56%)
At close: Jan 30, 2026
Ligand Pharmaceuticals Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Net Income | 48.58 | -4.03 | 52.15 | -33.36 | 57.14 | -2.99 |
Depreciation & Amortization | 34.19 | 35.24 | 36.52 | 38.32 | 50.95 | 27.97 |
Other Amortization | 2.91 | 2.61 | 1.98 | 6.26 | 21.53 | 24.69 |
Loss (Gain) From Sale of Assets | - | - | -2.12 | - | - | -17.11 |
Asset Writedown & Restructuring Costs | 4.08 | 30.57 | 0.92 | - | - | - |
Loss (Gain) From Sale of Investments | -106.67 | -43.44 | -47.68 | -28.52 | 4.11 | 18.41 |
Loss (Gain) on Equity Investments | 7.06 | 12.82 | 1.83 | - | - | - |
Stock-Based Compensation | 40.1 | 41.09 | 25.74 | 50.88 | 38.78 | 30.73 |
Other Operating Activities | 12.01 | 2.83 | 14.64 | 16.54 | -36.71 | -15.43 |
Change in Accounts Receivable | -25.32 | -6.46 | -2.6 | 55.32 | -28.62 | -26.06 |
Change in Inventory | 4.78 | 9.62 | -10.87 | 12.06 | -0.43 | -17.8 |
Change in Accounts Payable | 9.82 | 13.9 | -4.7 | -3.34 | 2.81 | -1.25 |
Change in Unearned Revenue | -0.71 | -1.31 | 0.42 | -6.28 | -17.87 | 29.24 |
Change in Income Taxes | 6.54 | 2.31 | -1.78 | 1.58 | -3.98 | 9.14 |
Change in Other Net Operating Assets | -5.47 | 1.29 | -14.87 | 6.34 | -8.93 | -4.95 |
Operating Cash Flow | 31.92 | 97.05 | 49.58 | 137.85 | 78.8 | 54.59 |
Operating Cash Flow Growth | -58.36% | 95.75% | -64.04% | 74.94% | 44.36% | - |
Capital Expenditures | -1.16 | -1.82 | -3.52 | -12.35 | -8.76 | -4.46 |
Cash Acquisitions | - | - | -10.41 | - | - | -404.88 |
Divestitures | - | - | - | - | - | 22.06 |
Sale (Purchase) of Intangibles | - | - | - | - | 0.49 | 1.36 |
Investment in Securities | -387.32 | -136.08 | 52.15 | 182.42 | 40.01 | 615.67 |
Other Investing Activities | -9.36 | -5.77 | -49.91 | -6.44 | -1.22 | 1.9 |
Investing Cash Flow | -397.84 | -143.66 | -11.68 | 163.62 | 30.52 | 231.65 |
Long-Term Debt Repaid | - | -0.03 | -76.9 | -261 | -164.95 | -231.76 |
Net Debt Issued (Repaid) | 346.72 | -0.03 | -76.9 | -261 | -164.95 | -231.76 |
Issuance of Common Stock | 60.65 | 102.73 | 22.45 | 3.23 | 33.76 | 3.02 |
Repurchase of Common Stock | -26.19 | -5.14 | -4.55 | -8.24 | -6.02 | -79.48 |
Other Financing Activities | 59.1 | -0.43 | -0.95 | -9.98 | -0.56 | -2.33 |
Financing Cash Flow | 440.28 | 97.14 | -59.95 | -275.99 | -137.76 | -310.55 |
Foreign Exchange Rate Adjustments | 1.4 | -1.17 | - | - | - | - |
Net Cash Flow | 75.76 | 49.35 | -22.05 | 25.48 | -28.44 | -24.31 |
Free Cash Flow | 30.76 | 95.23 | 46.06 | 125.5 | 70.04 | 50.13 |
Free Cash Flow Growth | -59.05% | 106.76% | -63.30% | 79.19% | 39.72% | - |
Free Cash Flow Margin | 12.24% | 56.98% | 35.07% | 63.95% | 29.00% | 30.65% |
Free Cash Flow Per Share | 1.58 | 5.21 | 2.59 | 7.44 | 4.06 | 2.98 |
Cash Interest Paid | 0.3 | 0.26 | 0.29 | 1.43 | 3.03 | 4.46 |
Cash Income Tax Paid | 7.04 | 19.21 | 8.77 | 11.64 | 3.72 | 2.13 |
Levered Free Cash Flow | 97.81 | 100.79 | 46.03 | 136.93 | 37.03 | 123.51 |
Unlevered Free Cash Flow | 99.31 | 102.2 | 46.2 | 137.33 | 32.6 | 117.57 |
Change in Working Capital | -10.35 | 19.36 | -34.4 | 65.68 | -57 | -11.67 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.